YKYu. V. Kotovskaya

Yu. V. Kotovskaya

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yu. V. Kotovskaya has a total of 671 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization of approaches to the diagnosis and treatment of vestibular vertigo in geriatric practice. Analytical review of the Expert Council resolution

    by V. A. Parfenov, O. N. Tkacheva, G. E. Ivanova, Yu. V. Kotovskaya, M. V. Zamergrad, A. L. Guseva, E. A. Mkhitaryan, O. V. Zaitseva, N. K. Runikhina, E. V. Baibakova, et al.

    At the Expert Council meeting on June 26, 2026, the issues of diagnosis and treatment of vestibular vertigo in the elderly were discussed. It was noted that the causes of peripheral vestibular vertigo in the elderly are most often benign paroxysmal positional vertigo, Meniere's disease, bilateral vestibulopathy, and presbyvestibulopathy. The most common causes of central dizziness are transient ischemic attacks, strokes, and migraine-associated dizziness. These common causes of dizziness are often undiagnosed; many elderly patients have an erroneous diagnosis of chronic cerebral ischemia, vertebrobasilar insufficiency, or cervical osteochondrosis and do not receive effective treatment. The management of elderly patients is based on the identification and effective treatment of the causes of vertigo, the use of vestibular rehabilitation, the correction of sensory deficits, and the identification and effective treatment of concomitant diseases. When selecting drug therapy, strict prevention of polypharmacy and adherence to safety criteria with minimization of the use of drugs that increase the risk of falls and cognitive impairment are of key importance. As a pharmacological potentiation of central adaptation, the use of betahistine dihydrochloride (for example, Betaserc Long 48 mg, a dosage form for once-daily administration) is justified. The development of specialty-specific clinical recommendations and standards for the management of elderly patients with vertigo and balance disorders is of great importance, which will reduce the risks of falls and improve the functional activity of patients.

  • Results of revascularization operations in geriatric patients with multifocal atherosclerosis

    by Z.A. Kavteladze, K.A. Eruslanova, P.M. Ermolaev, S.Y. Danilenko, N.K. Runikhina, M.R. Khokonov, A.M. Nikolaeva, M.M. Balaeva, Y.V. Kotovskaya, O.N. Tkacheva

    Background. Multifocal atherosclerosis (MFA) is one of the common diseases in elderly patients. Currently, there is no single approach to treating patients with MFA. The active implementation of endovascular surgery has significantly expanded the treatment options for comorbid elderly patients with MFA. Objective of the study: to evaluate the effectiveness and safety of various methods of surgical revascularization in geriatric patients with multifocal atherosclerosis. Materials and methods. This single-center observational cohort study was conducted in the Department of Cardiovascular Surgery at the Research and Clinical Center of the Russian National Research Medical University named after N.I. Pirogov. The study included 44 elderly patients with arterial diseases of various localizations. Two groups of patients were identified depending on the chosen treatment method: a group of patients undergoing endovascular treatment (n=30), and a group after open surgical procedures (n=14). Endovascular interventions: balloon angioplasty and/or stenting (carotid, iliac-femoral, popliteal-tibial, etc.), aortic endoprosthetic replacement (EVAR/TEVAR), endovascular reconstructions of visceral/renal arteries. Open surgeries: carotid endarterectomy, aortic prosthetic replacement/grafting/shunting, peripheral shunting, thromboendarterectomy, etc. All operations were performed as part of the routine schedule from June 2024 to June 2025. The choice of revascularization method was made by a multidisciplinary team. Results. An analysis of in-hospital complications was performed in 44 patients; no fatal cases were recorded during hospitalization. Postoperative delirium developed in 3 patients (2 in the endovascular treatment group and 1 in the open surgery group, p>0.05). Despite the less favorable initial geriatric and functional profile of patients undergoing endovascular surgery, early postoperative outcomes are comparable to the results in the group of patients who underwent open vascular surgery. To definitively assess the comparative effectiveness of treatment methods, larger-scale studies are needed, with careful adjustment for confounding factors, standardized collection of functional and patient-oriented outcomes, and analysis of long-term treatment results. Conclusion. Thus, with comparable risks of complications in elderly patients in the vascular surgery department with MFA and atherosclerotic lesions in various arterial territories, endovascular surgery allows for the operation of more “fragile” patients.

  • Open Access

    Contemporary sarcopenia diagnosis: evolving definitions, screening, and instrumental assessment – a narrative review

    by O. N. Tkacheva, E. N. Dudinskaya, Y. V. Kotovskaya, A. V. Naumov, N. O. Khovasova, B. I. Isaeva, K. O. Chepygova, О. Н. Ткачева, Е. Н. Дудинская, Ю. В. Котовская, et al.

    Sarcopenia currently affects 10–27% of people worldwide and 30–37% in the Russian Federation. Its social burden is considerable: the condition is associated with fractures, disability, and increased mortality. Sarcopenia nonetheless remains underdiagnosed. Diagnosis is hindered by the absence of universal criteria, standardized cutoff values, and widely available screening tools, while applying non-adapted foreign reference values to the Russian population may cause both under- and overdiagnosis. Aim. To analyze the evolution of international and Russian approaches to sarcopenia diagnosis, assess the diagnostic value and limitations of available screening and instrumental methods, and formulate proposals for optimizing diagnostic strategies in clinical practice in the Russian Federation. Materials and methods. A literature review on sarcopenia diagnosis was conducted using PubMed/MEDLINE, Scopus, Google Scholar, and eLibrary.ru for 2006–2026. Systematic reviews, meta-analyses, randomized controlled trials and cohort studies, consensus documents, and clinical guidelines were included. Results. A shift was observed from the isolated assessment of muscle mass toward diagnostic models in which muscle strength serves as the primary criterion and physical performance as an indicator of disease severity. Handgrip dynamometry cutoff values varied across populations. In particular, muscle strength in Russians older than 65 years was at the lower limit of European reference values. No screening instrument demonstrated both high sensitivity and high specificity. The most balanced instrument, SARC-CalF, has not been validated in the Russian population. Instrumental methods are highly accurate; however, their use is limited by high cost, limited availability, dependence on hydration status, and the lack of standardized protocols. Conclusion. To improve the effectiveness of sarcopenia diagnosis in Russia, national reference values should be developed, diagnostic protocols standardized, and screening instruments validated.


  • Open Access

    Comparative Efficacy of Rebamipide, Pantoprazole, and Their Combination for Gastroprotection in Patients with Atrial Fibrillation Receiving Direct Oral Anticoagulants: The Randomized REGATA Study

    by Natalya M. Vorobyeva, Irina P. Malaya, Vadim D. Zakiev, Antonina A. Masharova, Tatiana P. Pinchuk, Irina V. Kostomarova, Valentina S. Ostapenko, Yulia V. Kotovskaya, Olga N. Tkacheva

    Background: Patients with atrial fibrillation (AF) receiving direct oral anticoagulants (DOAC) are at an elevated risk of gastrointestinal (GI) mucosal damage and bleeding. Proton pump inhibitors (PPI) are conventional gastroprotectors, but their efficacy in the lower GI tract is limited. This study evaluated the efficacy and safety of rebamipide monotherapy and combination pantoprazole-rebamipide (P + R) therapy compared to pantoprazole monotherapy in this vulnerable population. Methods: In the randomized, parallel-group, open-label, single-center REGATA trial, 210 AF patients receiving DOAC were randomized (1:1:1) to three gastroprotective regimens (n = 70 each) for 24 weeks: pantoprazole monotherapy, rebamipide monotherapy, or their combination. Efficacy analyses were performed in the per-protocol population (n = 118: pantoprazole, n = 36; rebamipide, n = 39; P + R, n = 43). The primary and secondary outcomes included composite clinical GI events (bleeding classified by ISTH/BARC, ulcers/erosions, and severe dyspepsia) and biomarkers of mucosal barrier function (fecal zonulin and calprotectin). Results: The incidence of primary efficacy endpoint events was 13.9% (n = 5; 95% CI: 3.1–25.7) in the pantoprazole group, 10.3% (n = 4; 95% CI: 2.3–21.1) in the rebamipide group, and 9.3% (n = 4; 95% CI: 2.1–18.6) in the P + R group, successfully confirming the non-inferiority hypothesis for both experimental arms within the pre-specified margin of 10% (p < 0.05). Multivariable regression analysis showed that compared with pantoprazole monotherapy, rebamipide monotherapy demonstrated an odds ratio OR of 0.71 (95% CI: 0.18–2.88, p = 0.630), while the P + R therapy was associated with an OR of 0.64 (95% CI: 0.16–2.57, p = 0.525). No major GI bleeding events or fatalities occurred; a single episode of GI bleeding (ISTH minor/BARC Type 2) was recorded in the pantoprazole arm (2.8%). Fecal calprotectin levels significantly decreased in the rebamipide group (by 37.6%, from 139 to 78 µg/g; p < 0.001) and the P + R group (by 50.0%, from 135 to 61 µg/g; p < 0.001), while no significant changes were observed in the pantoprazole group (p = 0.530). Concurrently, fecal zonulin levels, reflecting intestinal epithelial permeability, fell by 45.1% in the rebamipide arm (from 434 to 225 ng/mL; p < 0.001) and by 47.1% in the P + R arm (from 347 to 182 ng/mL; p < 0.001) compared to a minimal 3.0% fluctuation in the pantoprazole group. Conclusions: While demonstrating non-inferiority regarding primary clinical endpoints, both rebamipide monotherapy and combination (P + R) therapy achieved some advantages over pantoprazole monotherapy in decreasing subclinical GI inflammation and restoring intestinal epithelial barrier integrity.

  • Open Access

    Arterial Hypertension and Cognitive Functions: Pathogenetic Mechanisms and Strategies for Prevention of Cognitive Impairment. Literature Review

    by N. G. Dudchenko, Yu. V. Kotovskaya, Н. Г. Дудченко, Ю. В. Котовская

    Population aging and the increasing prevalence of arterial hypertension (AH) have led to an epidemic of cognitive impairment and dementia. AH is a key modifiable risk factor that triggers a cascade of pathophysiological changes: cerebrovascular remodeling, blood-brain barrier (BBB) dysfunction, and neuroinflammation. Analysis of current data demonstrates that angiotensin II receptor blockers (ARBs), particularly telmisartan, possess unique neuroprotective properties due to their high affinity for AT1R and their ability to activate PPARγ. This provides anti inflammatory and antioxidant effects, as well as improved cerebral blood flow. Calcium channel blockers (CCBs), such as amlodipine, complement this effect by improving regional perfusion and reducing oxidative stress. The combination of telmisartan and amlodipine ensures not only stable blood pressure control and reduced variability but also multi-channel protection of the neurovascular unit.

  • Open Access

    Analysis of Reasons for the Cancellation of Elective Orthopedic Surgeries for Knee or Hip Arthroplasty in Patients Aged 75 and Older: Retrospective Study

    by M. M.-B. Balaeva, I. A. Solomyannik, E. E. Esenbekova, K. A. Eruslanova, Yu. V. Kotovskaya, М. М.-Б. Балаева, И. А. Соломянник, Э. Э. Эсенбекова, К. А. Ерусланова, Ю. В. Котовская

    INTRODUCTION : Surgical treatment in patients aged 75 years and older is associated with a high risk of intraand postoperative complications, leading to a significant number of cancellations of planned procedures. The cancellation of elective surgeries in elderly patients is a complex medical and organizational issue that has a negative impact on patients, medical institutions, and healthcare systems. OBJECTIVE : The aim of this study is to conduct a retrospective analysis of the reasons for cancellations of elective orthopaedic surgeries in patients 75 or older. MATERIALS AND METHODS : We analyzed the medical records of 109 patients scheduled for knee or hip arthroplasty in 2024. We reviewed the reasons for surgery cancellations in this cohort. RESULTS : Of the 109 planned surgeries in patients aged 75 and older, 55 (51%) were performed. Among the reasons for cancellations, clinical factors predominated, driven by high comorbidity: coronary artery disease, anemia, obesity, atrial fibrillation, oncological diseases, and other concomitant conditions. In some cases, the decision to cancel the surgery was related to the success of conservative therapy or a recent acute respiratory infection. Organizational reasons, primarily long waiting times, as well as episodes with unclear circumstances, also accounted for a significant proportion. Medico-social factors were represented by patient refusal due to fear of surgical intervention, or the inability to provide postoperative care. During follow-up, about half of the previously cancelled interventions were subsequently performed; however, a significant portion remained unrealized. CONCLUSIONS : Every second planned surgical intervention for patients aged 75 years and older was canceled. The key risk factors for cancellation include comorbidities as well as organizational barriers. It is necessary to conduct a comprehensive geriatric assessment in order to optimize preoperative patient preparation and minimize risks, as well as improve patient flow in elective surgery.

  • Open Access

    Multicomponent Rehabilitation Programs for Frailty: Analysis of the Multicenter Prospective Study «POSTSCRIPTUM»

    by A. V. Luzina, N. K. Runikhina, O. N. Tkacheva, Yu. V. Kotovskaya, A. A. Arefieva, M. S. Arefieva, E. E. Popov, T. A. Bondarenko, V. S. Ostapenko, Yu. S. Onuchina, et al.

    BACKGROUND . Older adults with multiple comorbidities often have limitations in their daily activities due to the development of geriatric syndromes, such as frailty, malnutrition, and falls. The level of functional activity decreases significantly [1]. The approach to improving functional activity in these patients involves implementing multicomponent programs, including physical exercise [2]. However, there is no consensus among specialists on the effectiveness, structure, and duration of these interventions for multimorbid weakened elderly patients. OBJECTIVE . To evaluate the structure of individual multicomponent rehabilitation programs based on the results of a comprehensive geriatric assessment of multimorbid patients aged 60 and older with frailty syndrome. MATERIALS AND METHODS . The study was conducted at the Russian Gerontology Research and Clinical Center (RGNCC) of the N. I. Pirogov Russian National Research Medical University. Individual multicomponent programs were analyzed based on the results of comprehensive geriatric assessment (CGA) in patients with multimorbidity and frailty. The study included 299 patients, 79% of whom were women. The median age was 75 years (70; 81). All patients underwent CGA with functional and neuropsychological testing to identify geriatric syndrome (GS). Based on the CGA results, individualized geriatric rehabilitation (GR) programs were developed for each patient. These programs consist of 22 exercises, ranked by intensity in five levels, ranging from less intense (level 1) to more intense (level 5), with a specified number of repetitions and sets: 9 anaerobic exercises, one aerobic (cardiovascular) exercise (walking), five balance exercises and seven stretching exercises. Individualized long-term intervention programs also include recommendations on nutrition, cognitive training, use of walking aids and correction of any deficiencies identified during CGA. RESULTS . In the structure of functional deficits, mobility impairments and the risk of falls, according to the results of the Brief Battery of Physical Functioning Tests (BBPFT) and the «Stand up and go» test, 39.0% of patients were identified. The majority of these patients (88.4%) showed a decrease in muscle strength in the upper limbs and a decrease in functional status, including instrumental activity in 47.9% of cases, dependency in everyday life for 43.1%, cognitive impairment for 33.4%, risk of depression for 24.1%, sleep disorders for 44.6%, polypharmacy for 47.3%, chronic pain syndrome for 78.8%, malnutrition for 20.9%. The most common chronic noncommunicable diseases were hypertension (93.0%), cerebrovascular accidents (47.2%), chronic kidney disease (49.8%), osteoarthritis (41.5%), coronary heart disease (29.4%), and type 2 diabetes mellitus (27.4%). Almost every fifth patient has a history of stroke. In 58% of patients, the duration of exercise did not exceed 30 minutes per day. Based on the identified goals and deficiencies, rehabilitation programs were developed for functional activity using adapted physical exercises, considering the level of physical activity (100% of cases), cognitive training (43.6%), and correction of the psychoemotional state (depression, insomnia, 77.8%), nutrition (29.8%) and fall prevention (77.8%). CONCLUSION . Elderly and very old patients form a heterogeneous group with a variety of comorbidities, requiring an individualized approach to selecting rehabilitation programs. Comprehensive geriatric rehabilitation programs, developed based on the results of comprehensive geriatric assessments, address the fullest possible range of needs for patients with frailty.

  • Open Access

    Review of Clinical Guidelines «Sarcopenia in Elderly Patients»

    by O. N. Tkacheva, A. M. Lila, N. N. Zubareva, V. A. Tutelyan, Yu. V. Kotovskaya, N. K. Runikhina, A. V. Naumov, E. N. Dudinskaya, N. O. Khovasova, N. V. Sharashkina, et al.

    This review outlines the key points from the clinical guidelines «Sarcopenia in Elderly Patients», covering definition, epidemiology, clinical features, diagnostic approaches, and treatment strategies. The information is intended to help individuals manage patients aged 60 years or older with a focus on muscle health.

  • Open Access

    Geriatric status characteristics in patients with rheumatoid arthritis aged over 65 years: A subanalysis of the Russian EUCALYPT study

    by A. D. Meshkov, N. M. Vorobyeva, I. P. Malaya, N. O. Khovasova, A. V. Naumov, Yu. V. Kotovskaya, O. N. Tkacheva, А. Д. Мешков, Н. М. Воробьёва, И. П. Малая, et al.

    The aim – to study the features of geriatric status in patients with rheumatoid arthritis (RA) aged ≥65 years. Materials and methods . The EUCALYPT study enrolled 4308 people (30% men) aged 65 to 107 years (median 78 years) residing in 11 regions of the Russian Federation. A comprehensive geriatric assessment, consisting of a survey using a specially developed questionnaire and an objective examination, was performed for all participants. The presence of RA in the subjects was determined based on records in their medical charts. Information on the presence or absence of RA was available for 4295 (99.7%) patients. Results. The prevalence of RA among all patients was 6.9%, including 7.6% among individuals aged 65–74 years, 7.5% among those aged 75–84 years, and 5.2% among those aged ≥85 years (p=0.026). The prevalence of RA in women was 1.4 times higher than in men (7.6% vs. 5.3%; p=0.005). Univariate regression analysis showed that with each additional year of age the odds of having RA decreased by 2% (odds ratio ( R) – 0.98; 95% confidence interval (95% CI): 0.97–0.997; p=0.019), whereas women had 49% higher odds of having RA (OR=1.49; 95% CI: 1.12–1.97; p=0.005). Compared with patients without RA, the geriatric status of patients with RA was somewhat worse, as they had a higher prevalence of a number of geriatric syndromes (GS): chronic pain (97.6% vs. 86.4%; pConclusion . The EUCALYPT study provided, for the first time, domestic (Russian) data on the prevalence of RA in individuals aged ≥65 years and examined the associations between RA and GS.

  • Open Access

    Pneumococcal infection in the elderly: cost-effectiveness of vaccination to reduce demographic losses

    by A. V. Rudakova, S. N. Avdeev, L. S. Namazova-Baranova, O. N. Tkacheva, Y. V. Kotovskaya, R. V. Polibin, A. V. Kontsevaya, R. N. Shepel, L. Yu. Drozdova, O. M. Drapkina, et al.

    Aim . To assess cost-effectiveness for vaccinating people ≥60 years against pneumococcal infection. Material and methods . Markov modeling was conducted using epidemiological data for the Russian Federation for people aged ≥60 years. The cost-effectiveness of monovaccination with a 23-valent polysaccharide vaccine (PPV23), sequential immunization with a 13-valent conjugate vaccine (PCV13) followed by PPV23 one year later, and vaccination with a 20-valent conjugate vaccine (PCV20) were assessed. The analysis was conducted from the perspective of society as a whole and from the healthcare system. The study time horizon was 10 years. Vaccine costs were analyzed based on registered prices, including VAT. Costs and quality-adjusted life expectancy were discounted by 3% per year. A sensitivity analysis assessed the cost-effectiveness of changing the price of PCV20 by 15% and reducing the time horizon to 5 years. Results . PCV20 vaccination reduces the incidence of pneumococcal infection compared to monovaccination with PPV23 and sequential PCV13/PPV23 immunization. When vaccinating individuals ≥60 years, the incremental cost per additional quality-adjusted life year (QALY) from a societal perspective would be RUB3,684,400, RUB2,087,300, and RUB1,385,600 for PPV23, PCV13/PPV23, and PCV20 vaccination, respectively. When analyzed from a healthcare system perspective, the cost-effectiveness ratios are RUB3,908,100/QALY, RUB2,288,700/ QALY, and RUB1,585,300/QALY for vaccination with PPV23, PCV13/ PPV23, and PCV20, respectively. A sensitivity analysis demonstrated the reliability of the obtained data. Conclusion . Vaccination of Russian people aged ≥60 years with PCV20 provides the greatest reduction in pneumococcal infection incidence and is highly cost-effective compared to PPV23 vaccination and is cost-effective compared to sequential PCV13/PPV23 vaccination. All vaccination options are cost-effective compared to no vaccination.